LIGHTBEAM-U01 Substudy 01A: A Phase 1/2 Substudy to Evaluate the Safety and Efficacy of Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 05 Mar 2025

Price :

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

Drugs Zilovertamab vedotin (Primary)
Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Ewing's sarcoma; Follicular lymphoma; Mantle-cell lymphoma; Neuroblastoma; Precursor B-cell lymphoblastic leukaemia-lymphoma; Richter's syndrome; Solid tumours
Focus Adverse reactions; Therapeutic Use
Acronyms LIGHTBEAM-U01 Substudy 01 A
Sponsors ATAI Life Sciences; Merck Sharp & Dohme Corp.

20 Aug 2024 Planned initiation date changed from 13 Aug 2024 to 31 Aug 2024.
05 Aug 2024 Planned initiation date changed from 27 Jun 2024 to 13 Aug 2024.
24 Jun 2024 Planned initiation date changed from 4 Jun 2024 to 27 Jun 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com